Asahi Kasei Pharma obtains rights to additional indication of Doptelet® thrombopoietin receptor agonist
March 29, 2024
Asahi Kasei Pharma Corp.
Asahi Kasei Pharma has concluded an agreement with Swedish Orphan Biovitrum Japan Co., Ltd. (Sobi Japan) regarding exclusive distribution rights in Japan for the additional indication of idiopathic thrombocytopenic purpura (immune thrombocytopenia)1 for Doptelet®, a thrombopoietin receptor agonist, (generic name: avatrombopag maleate).
Doptelet® was approved in Japan in March 2023 as an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure2, and Asahi Kasei Pharma began marketing it in June 2023 based on exclusive distribution rights from Sobi Japan. For the treatment of idiopathic thrombocytopenic purpura (immune thrombocytopenia), Doptelet® has been approved in the U.S., Europe, etc., and is currently the subject of a Phase III clinical study in Japan by Sobi, Inc.
Through the agreement announced today, Asahi Kasei Pharma obtains exclusive distribution rights for Doptelet® in Japan for the additional indication of idiopathic thrombocytopenic purpura (immune thrombocytopenia).
By providing a new therapeutic option for idiopathic thrombocytopenic purpura (immune thrombocytopenia) in addition to thrombocytopenia in patients with chronic liver disease, Asahi Kasei Pharma aims to realize a society where “no one should have to give up doing what they love due to illness” in accordance with its mission “to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science.”
About Swedish Orphan Biovitrum AB
Founded in 2009, Sobi is a specialized international biopharmaceutical company headquartered in Stockholm, Sweden, transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, and Asia. To learn more, visit https://www.sobi.com/
- 1A disease with decreased platelet counts in the absence of other diseases or medications that would lead to an increased risk of bleeding. Symptoms may include reddish-purple spots on the skin (purpura), nosebleeds, and bleeding from gums.
- 2Invasive procedures such as upper gastrointestinal endoscopy, radiofrequency ablation and transarterial chemoembolization (TACE) for hepatocellular carcinoma, etc.